Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva’s Cubicin Authorized Generic Is First Rival To Merck’s Brand

Executive Summary

Teva launched an authorized generic version of Merck’s blockbuster antibiotic, while Pfizer did not provide an update on the timeline of a generic launch for which a court decision paved the way.


Related Content

Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
Pfizer Finally Sealing Hospira Deal
Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
Market Snapshot: Gram-Negative Antibiotics Progress As Urgency Grows
Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth


Related Companies